-
Research and Reports in Urology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Sipuleucel-T: immunotherapy for advanced prostate cancer
Review
(1829) Views (407) Full article downloads
Authors: Olson BM, McNeel DG
Published Date May 2011
Volume 2011:3 Pages 49 - 60
DOI: http://dx.doi.org/10.2147/RRU.S13069
Brian M Olson, Douglas G McNeel
University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA
Abstract: Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient's own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer.
Keywords: sipuleucel-T, prostatic acid phosphatase, granulocyte-macrophage colonystimulating factor
Readers of this article also read:
A review and empirical study of the composite scales of the Das–Naglieri cognitive assessment system
Recent advances in the management of chronic stable angina I: Approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities
Exercise for people with hip or knee osteoarthritis: a comparison of land-based and aquatic interventions
Molecular biocoding of insulin
Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter?
The treatment of female stress urinary incontinence: an evidenced-based review
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
Contrast-induced nephropathy in interventional cardiology
Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Distal femoral opening-wedge osteotomy for lateral compartment osteoarthritis of the knee
- Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
- Neurotransmitter testing of the urine: a comprehensive analysis
- Ipsilateral pedicle screw placement with contralateral percutaneous facet screws: Early results with an alternative in lumbar arthrodesis




